- Home
- Platforms
- ImmuBridge™️ : Multispecific Antibody Platform and Next-Generation TCEs
- BiTE Antibody Development
In the realm of cutting-edge biological research, the development of bispecific T cell engager (BiTE) antibodies has emerged as a revolutionary approach in cancer therapy. This innovative technology, with its unique design and mechanism of action, holds significant promise in the treatment of various malignancies. Leveraging the ImmunBridge™ platform, our company stands at the forefront of BiTE antibody development, driving advances that redefine the landscape of oncological interventions.
Bispecific T cell engager (BiTE) is a common multispecific antibody construct designed to redirect T cells towards target cells expressing specific antigens. These antibodies consist of two single-chain variable fragments (scFvs) linked in tandem, one binding to a T cell antigen (usually CD3) and the other binding to a tumor cell antigen. This structure allows for the formation of a bridge between the T cell and the tumor cell, leading to T cell-mediated killing of the tumor cell.
Fig. 1 The principle of action of the BiTE antibodies. (Viardot A, et al., 2020)Precise Targeting
BiTE antibodies enable precise targeting of tumor cells, reducing off-target effects and minimizing damage to healthy tissues.
Potent Immune Activation
BiTE antibodies activate T cells, promote the release of cytotoxic molecules, and enhance the body's natural immune response to cancer.
Rapid Action
Due to their mechanism of action, BiTE antibodies can induce rapid killing of target tumor cells within hours of administration.
Versatility
BiTE antibodies can be customized to address diverse disease mechanisms, making them versatile tools in the development of novel therapeutics.
With the ImmuBridge™ multispecific antibody platform and expertise in antibody engineering, our scientists meticulously design and refine highly specific BiTE antibodies targeting multiple tumor antigens. Through iterative in vitro screening and preclinical validation, we are committed to developing customized BiTE antibody constructs to target specific cancer cells with precision and efficiency.
One of our notable accomplishments in BiTE antibody development involves the creation of targeted antigen (TA)/CD3 BiTE antibodies. TA/CD3 BiTE antibodies are designed to target tumor-specific antigens on cancer cells and CD3 receptors on T cells simultaneously. By linking these cell types, they activate T cells to selectively eliminate cancer cells expressing the antigen, ensuring targeted destruction without harming healthy tissues.
Fig. 1 Structure of the tumor antigen (TA)/CD3 BiTE antibody.TA/CD3 BiTE antibodies have emerged as powerful tools in the arsenal of cancer immunotherapy, offering precise and potent immune-mediated responses against malignant cells. The versatility of TA/CD3 BiTE antibodies extends to a wide array of cancers, with notable applications including:
HER2-Positive Breast Cancer
HER2/CD3 BiTE antibodies have demonstrated efficacy in HER2-positive breast cancer by directing T cells to eradicate HER2-expressing tumor cells. This approach offers a precise and targeted strategy for combating this aggressive form of breast cancer.
EpCAM-Positive Solid Tumors
EpCAM/CD3 BiTE antibodies have shown promise in targeting EpCAM-positive solid tumors such as colorectal and gastric cancers. By engaging T cells in the destruction of EpCAM-expressing cancer cells, these antibodies present a novel therapeutic avenue for individuals with these malignancies.
CD19-Positive Hematological Malignancies
The CD19/CD3 BiTE antibody has markedly transformed the therapeutic paradigm for CD19-positive hematologic malignancies such as acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma, bringing hope for therapeutic intervention in affected individuals.
The ImmuBridge™ multispecific antibody platform stands as a pioneering breakthrough in the realms of oncology and immunotherapy. Through the creation of bispecific T cell engagers (BiTEs), we surmount the constraints associated with traditional monoclonal antibodies, effectively redirecting T cells to specific tumor cells with heightened precision and specificity, thus enabling broader cancer therapeutic applications.
We are open to collaboration or licensing of our platform. We are also actively seeking partners to co-develop BiTE antibody drug candidates. Please feel free to contact us to explore potential collaboration opportunities.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Our ImmuBridge™️ platform is specifically designed for developing multispecific antibodies targeting tumor antigens. We provide comprehensive research services for cancer immunotherapy to drive advancements in the field.